Advertisement

Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 600x60px
Document › Details

Celyad S.A.. (9/21/17). "Press Release: Celyad to Present at the Cantor Fitzgerald Global Healthcare Conference". Mont-Saint-Guibert.

Organisations Organisation Celyad S.A. (Euronext Brussels + Paris: CYAD, Nasdaq: CYAD)
  Group Celyad (Group)
  Organisation 2 Cantor Fitzgerald & Co.
  Group Cantor Fitzgerald (Group)
Products Product Cantor Fitzgerald Healthcare Conference 2017 New York
  Product 2 CYAD-01 (CAR-T NKG2D) CAR-T cell therapy
Index term Index term Celyad–Cantor Fitzgerald: investor conference, 201709 supply service Celyad presents at Cantor Fitzegerald Global Healthcare Conference in NY
Persons Person Jeanmart, Patrick (Cardio3 BioSciences 201312 CFO)
  Person 2 Gilham, David (Celyad 201609– VP RnD before Univ Manchester MCRC + Bristol Univ)
     


Celyad (Euronext Brussels and Paris, and NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced that Patrick Jeanmart, Chief Financial Officer and David Gilham, VP Research and Development of Celyad will present a corporate update at the upcoming Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27th, 2017 at 2:15 p.m. ET in New York, NY.

A live audio webcast of the presentation will be available on the Investor Relations section of Celyad’s website at http://wsw.com/webcast/cantor6/cyad/, where it will be archived for approximately 90 days.


About Celyad

Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell based therapies. Celyad utilizes its expertise in cell engineering to target cancer. Celyad’s Natural Killer Receptor based T-Cell (NKR-T) platform has the potential to treat a broad range of solid and hematologic tumors. Its lead oncology candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a single dose escalation Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers including five solid tumors (colorectal, ovarian, bladder, triple-negative breast and pancreatic cancers) and two hematological tumors (acute myeloid leukemia and multiple myeloma). Celyad was founded in 2007 and is based in Mont-Saint-Guibert, Belgium, and Boston, Massachusetts. Celyad’s ordinary shares are listed on the Euronext Brussels and Euronext Paris exchanges, and its American Depository Shares are listed on the NASDAQ Global Market, all under the ticker symbol CYAD.

   
Record changed: 2017-10-04

Advertisement

Picture EBD Group Biotech Showcase 2019 San Francisco BTS January 600x60px

More documents for Celyad (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Bio-Europe Spring 2019 Vienna Austria March 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 120x240px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Picture Berlin Partner HealthCapital Bionnale 2018 June Matchmaking 120x240px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Biotech Showcase 2019 San Francisco BTS January 120x180px Picture EBD Group Bio-Europe 2018 Copenhagen Denmark November 120x180px